Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.

Completed · Early Phase 1

Conditions studied: Idiopathic Pulmonary Fibrosis

In brief

This is a two part study. In the first part, the pharmacokinetic profile of Epigallocatechin-3-gallate (EGCG) in normal human volunteers given a single oral dose will be determined to set the dose for the second part of the study. In the second part of this study, lung biopsy fragments and urine samples from patients with interstitial lung disease treated with EGCG will be evaluated in biochemical assays and compared to samples from untreated control patients.

Key facts

Study ID

NCT03928847

Run by

Hal Chapman

People needed

35

Starts

2017-12-01

Expected to finish

2019-05-31

Last updated by the study team

2022-12-22

Who can join

Age: 40 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Part 1: healthy volunteers
• Part 2:
• study will consist of patients presenting to the UCSF interstitial lung disease (ILD) outpatient clinic with imaging indicative of lung fibrosis but of uncertain classification, and who are willing to take EGCG for a minimum of 2 weeks prior to surgery.

You may not qualify if…

• co-morbidities affect hepatic function, such as HCV infection, cirrhosis, or
• using drugs with significant hepatic toxicities

Where it is running

• UC San Francisco — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.